2018•国际医药卫生导报Requires access
Alprostadil combined with benazepril in treatment of diabetic nephropathy proteinuria
Xuemei He
Open publisher page 0 citations
Abstract
Objective
To investigate the efficacy of alprostadil combined with benazepril in the treatment of diabetic nephropathy proteinuria.
Methods
From March, 2016 to October, 2017, 84 cases of diabetic nephropathy admitted into our hospital were selected, and were randomly divided into an observation group and a control group, 42 for each group. The control group were treated with alprostadil injection, and the observation group with alprostadil and benazepril. The 24 h urine protein content, 24 h urine albumin excretion rate, and adverse reaction of the two groups before and after 7 weeks of treatment were compared.
Results
The 24 h urinary albumin excretion rate and 24 h urinary protein content were significantly lower in the observation group than in the control group 7 weeks after the treatment (t = 2.627 and 25.074, P = 0.010 and 0.000). There was no statistical difference in the incidence of adverse reactions between the observation group and the control group (7.14% vs. 11.90%, χ2= 0.553, P = 0.457).
Conclusion
Alprostadil combined with benazepril in the treatment of diabetic nephropathy is effective and can significantly decrease 24 h urinary protein excretion and 24 h urinary albumin excretion rate, so it worth for clinical application.
Key words:
Benazepril; Alprostadil; Diabetic nephropathy; Proteinuria